---
title: 6. Further information
---

import Expander from '../../../src/components/Expander'

British National Formulary—available online

Martindale: the complete drug reference—available online

NICE. [Schizophrenia: Core interventions in the treatment and management of schizophrenia in adults in primary and secondary care](http://publications.nice.org.uk/schizophrenia-cg82) – clinical guideline 82 (issued March 2009)

Barnes TRE, et al. Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology. *J Psychopharmacol* 2011; **25:** 567–620

**Information from MHRA**

**Note.** References to older MHRA[^1] advice is included for background only; the information will have been incorporated into summaries of product characteristics and some will have been superseded.

  


<table>
 <tr>
  <th>
   <p>
    Source
   </p>
  </th>
  <th>
   <p>
    Article title
   </p>
  </th>
  <th>
   <p>
    Comment
   </p>
  </th>
 </tr>
 <tr>
  <td>
   <p>
    Drug Safety Update September 2011
   </p>
  </td>
  <td>
   <p>
    <a href="http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON128953">
     Antipsychotics: use during third trimester of pregnancy and extrapyramidal effects or withdrawal symptoms in newborns
    </a>
   </p>
  </td>
  <td>
   <p>
    Risk of extrapyramidal effects and withdrawal effects in newborns born to mothers on antipsychotics during the third trimester
   </p>
  </td>
 </tr>
 <tr>
  <td>
   <p>
    Drug Safety Update April 2011
   </p>
  </td>
  <td>
   <p>
    <a href="http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON111764">
     Atypical (second-generation) antipsychotics: reminder to monitor and manage weight, glucose, and lipid levels
    </a>
   </p>
  </td>
  <td>
  </td>
 </tr>
 <tr>
  <td>
   <p>
    MHRA website March 2010
   </p>
  </td>
  <td>
   <p>
    <a href="http://www.mhra.gov.uk/Safetyinformation/Generalsafetyinformationandadvice/Product-specificinformationandadvice/Product-specificinformationandadvice-A-F/Antipsychoticdrugs/index.htm">
     Antipsychotic drugs
    </a>
   </p>
  </td>
  <td>
   <p>
    Uses of antipsychotics, mechanism of action, side-effects and use in elderly people with dementia
   </p>
  </td>
 </tr>
 <tr>
  <td>
   <p>
    Drug Safety Update June 2009
   </p>
  </td>
  <td>
   <p>
    <a href="http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON087938">
     Antipsychotics: risk of venous thromboembolic events
    </a>
   </p>
  </td>
  <td>
   <p>
    Before and during treatment with antipsychotics, risk factors for venous thromboembolism should be identified and addressed
   </p>
  </td>
 </tr>
 <tr>
  <td>
   <p>
    Drug Safety Update March 2009
   </p>
  </td>
  <td>
   <p>
    <a href="http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON088116">
     Antipsychotics: use in elderly people with dementia
    </a>
   </p>
  </td>
  <td>
   <p>
    Antipsychotics may increase risk of stroke and slightly increase risk of early death in the elderly
   </p>
  </td>
 </tr>
 <tr>
  <td>
   <p>
    Pharmacovigilance Working Party assessment report
   </p>
  </td>
  <td>
   <p>
    <a href="../../assets/con2024914.pdf">
     Antipsychotics and cerebrovascular accident
    </a>
   </p>
  </td>
  <td>
   <p>
    Basis for the introduction of warning on cardiovascular adverse events into summaries of product characteristics
   </p>
  </td>
 </tr>
</table>





[^1]: Medicines and Healthcare products Regulatory Agency, the government body which regulates many aspects of the testing, manufacture, supply, and use of medicines and medical devices
